PRA raising $375M; U.K. pushes for trial transparency;

> PRA is raising $375 million in senior notes, cash that'll come in handy once private equity owner KKR merges it with ReSearch Pharmaceutical Services. More

> CRO Veristat is pitching in on Verastem's ($VSTM) trial of defactinib, an in-development drug designed to treat malignant pleural mesothelioma. News

> The U.K. is moving forward with a new rule that would require sponsors to register their clinical trials in a public database. Article

> Enrollment specialist Acurian, recently acquired by PPD, has released data touting the effectiveness of its patient-engagement services. Item

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.